Featured Cover Konstorum, Anna; Mohanty, Subhasis; Zhao, Yujiao ...
Aging cell,
February 2023, Letnik:
22, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Cover legend: The cover image is based on the Research Article Platelet response to infl uenza vaccination refl ects effects of aging by Anna Konstorum et al., https://doi.org/10.1111/acel.13749. ...Image Credit: Hannah Wang
Polio vaccination to resume across Afghanistan Roberts, Leslie
Science (American Association for the Advancement of Science),
2021-Oct-22, 2021-10-22, 20211022, Letnik:
374, Številka:
6566
Journal Article
Recenzirano
Success depends on shoring up the country’s health system
Success depends on shoring up the country’s health system
Background: After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or heterologous boosters (Sputnik ...V, ChAdOx, Pfizer-BioNTech, Moderna) against SARS-CoV-2 infections, hospitalisations and deaths has been scarcely studied. Methods: Test-negative, case–control study, conducted in Argentina during omicron BA.1 predominance, in adults ≥50 years old tested for SARS-CoV-2 who had received two or three doses of COVID-19 vaccines. Outcomes were COVID-associated infections, hospitalisations and deaths after administering mRNA and vectored boosters, < or ≥60 days from the last dose. Findings: Of 422,124 individuals tested for SARS-CoV-2, 221,993 (52.5%) tested positive; 190,884 (45.2%) and 231,260 (54.8%) had received 2-dose and 3-dose vaccination schemes, respectively. The 3-dose scheme reduced infections, hospitalisations and death (OR 0.81 0.80–0.83; 0.28 0.25–0.32 and 0.25 0.22–0.28 respectively), but protection dropped after 60 days to 1.04 1.01–1.06; 0.52 0.44–0.61 and 0.38 0.33–0.45). Compared with 2-dose-schemes, homologous boosters after primary schemes with vectored-vaccines provided lower protection against infections < and ≥60 days (0.94 0.92–0.97 and 1.05 1.01–1.09, respectively) but protected against hospitalisations (0.30 0.26–0.35) and deaths (0.29 0.25–0.33), decreasing after 60 days (0.59 0.47–0.74 and 0.51 0.41–0.64, respectively). Heterologous boosters protected against infections (0.70 0.68–0.71) but decreased after 60 days (1.01 0.98–1.04) and against hospitalisations and deaths (0.26 0.22–0.31 and 0.22 0.18–0.25, respectively), which also decreased after 60 days (0.43 0.35–0.53 and 0.33 0.26–0.41, respectively). Heterologous boosters protected against infections when applied <60 days (0.70 0.68–0.71, p < 0.001), against hospitalisations when applied ≥60 days (0.43 0.35–0.53, p < 0.01), and against deaths < and ≥60 days (0.22 0.18–0.25, p < 0.01 and 0.33 0.26–0.41, p < 0.001). Interpretation: During omicron predominance, heterologous boosters such as viral vectored and mRNA vaccines, following Sputnik V, ChAdOx1, Sinopharm or heterologous primary schemes might provide better protection against death; this effect might last longer in individuals aged ≥50 than homologous boosters. Funding: None.
